Weigao Group Adds 0.46 Million H-Shares to Treasury; Outstanding Float Drops to 4.45 Billion

Bulletin Express11-18 19:41

Shandong Weigao Group Medical Polymer Company Limited (abbreviated “Weigao Group”) disclosed a further buyback of 0.46 million H-shares on 18 November 2026, executed on the Hong Kong Stock Exchange under its existing repurchase mandate approved on 29 May 2026.

• Transaction details: 460,000 shares were repurchased at prices between HKD 3.175 and HKD 3.26, translating into a volume-weighted average of HKD 3.2193 and an aggregate outlay of HKD 1.48 million.

• Capital structure impact: – Issued shares outstanding (excluding treasury shares) fell from 4.45176 billion to 4.45130 billion. – Treasury shares increased from 70.57 million to 71.03 million, now representing approximately 1.57 % of total issued shares of 4.52 billion. – The repurchase equates to 0.0103 % of Weigao Group’s pre-transaction share base.

• Mandate utilisation: The company is authorised to buy back up to 446.46 million shares. Cumulative purchases since the mandate’s adoption total 13.71 million shares, or 3.07 % of the share count in place on the mandate date.

• Holding status: All shares acquired on 18 November 2026 are held as treasury shares; none have been cancelled.

• Post-transaction restrictions: In line with Hong Kong listing rules, Weigao Group is subject to a moratorium on new share issues or treasury-share disposals until 19 December 2026.

The board confirms that the latest repurchase complied with all applicable regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment